20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T22282 | Brr2-IN-3 | Brr2 Inhibitor 9,Brr2 Inhibitor C9 | Others |
Brr2-IN-3 (Brr2 Inhibitor C9) is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa (a group of progressive retinal degenerative disorders). | |||
T77662 | DJ4 | Apoptosis | |
DJ4 induces a dose-dependent pro-apoptotic effect in the micromolar range. | |||
T31675 | Esaprazole | C/63 | Others |
Esaprazole (C/63) has a dose - dependent cellular protective effect on the human gastric mucosa. | |||
TN1182 | 11-Keto-beta-boswellic acid | 11-Keto-beta-boswellic acid | Leukotriene Receptor , NF-κB , Lipoxygenase |
11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor; it exerts dose dependent cardioprotective effect manifested by dose-dependent reduction in serum lactate dehydrogenas... | |||
T6985 | Benzo[a]pyrene | 3,4-Benzopyrene | Others |
Benzo[a]pyrene (3,4-Benzopyrene) shows lung carcinogenicity in mice in a dose-dependent manner. | |||
T19552 | RPH-2823 | Others | |
RPH-2823, a basic amphotericin analog, is diuretic, natriuretic, and potassium-preserving, inducing a dose-dependent decrease in SCC and an increase in trans-epithelial resistance. | |||
T68174 | Sergliflozin A | SGLT | |
Sergliflozin A is a selective SGLT2 inhibitor that induces diabetes in a dose-dependent manner. It reduces hyperglycemia. | |||
TN1071 | Ophiopogonin D' | Sirtuin , UGT | |
Ophiopogonin D' can activate SIRT1 in a dose-dependent manner. Ophiopogonin D' also noncompetitively inhibits UGT1A6 and UGT1A10. | |||
TN7126 | N-Vanillyloctanamide | Others | |
N-Vanillyloctanamide is a capsaicinoid from the fruits of Capsicum annuum L. var. annuum. N-Vanillyloctanamide reduces the radical length of Lactuca sativa seedling, this inhibition being dose-dependent. | |||
T30819 | CGP 20376 | CGP-20376,CGP20376 | |
CGP 20376 is a benzothiazole compound, an anthelmintic, with dual dose-dependent modulation of in vitro effects on the respiratory burst of eosinophils and antifibrillatory properties. | |||
T38562 | AKN-028 | FLT | |
AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation. | |||
T6464 | Detomidine hydrochloride | MPV-253 AII,Domosedan,Detomidine HCl | Adrenergic Receptor |
Detomidine hydrochloride (MPV-253 AII) produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors. | |||
TN2058 | Persicogenin | Anti-infection | |
Persicogenin has anticancer, antimutagenic, and antileishmanial activities, it can inhibit the proliferation of mouse tsFT210 cancer cells, it mainly inhibits cell cycle at the G2/M phase in a dose-dependent manner. | |||
T10276 | AKT Kinase Inhibitor | Akt | |
AKT Kinase Inhibitor is an Akt inhibitor with antitumor activity that selectively inhibits cell proliferation in a dose-dependent manner. | |||
T6S1843 | Tenacissoside I | Tenacissimoside B | Others |
Tenacissoside I (Tenacissimoside B),Tenacissosides B, C and marsdenoside K inhibit the proliferation of Raji, NB4 and K562 cells in vitro significantly, in a dose and time dependent manner. | |||
T3042 | JAK2 Inhibitor V | JAK2 Inhibitor V Z3,Z3 | JAK |
JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner. | |||
TN1558 | N-Vanillyldecanamide | Decylic acid vanillylamide | Others |
N-Vanillyldecanamide (Decylic acid vanillylamide), isolated from fruits of Capsicum annuum, significantly reduced free radical length in alfalfa seedlings in a dose-dependent manner. | |||
T71746 | Pincainide | Others | |
Pincainide is a novel beta-aminoaniline that inhibits, in a dose-dependent manner, diseases caused by abnormal norepinephrine vascular smooth muscle function. | |||
T2299 | BMS-833923 | XL-139 | Apoptosis , Hedgehog/Smoothened , Smo |
BMS-833923 (XL-139), an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM). | |||
T36478 | BI-6901 | CCR | |
BI-6901 is a CCR10 antagonist. In a mouse model of DNFB exposure hypersensitivity, BI 6901 displays its anti-inflammatory response in a dose-dependent manner. |